Amarin Corporation plc · NASDAQ:AMRN
Amarin — Investor Presentation (February 2012)
22 slides from Amarin's investor presentation, February 2012
Slide 1: Managing Lipids for Improved Cardiovascular Health
Managing Lipids for Improved Cardiovascular Health INVESTOR PRESENTATION February 2012 Nasdaq: AMRN
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements, including those relating to Amarin’s product development, clinical and regulatory timelines, potential FDA approval, intellectual property, market opportunity, cash flow and other statements that are predictive in natur
Slide 3: Amarin: Focused on Cardiovascular Solutions
Amarin: Focused on Cardiovascular Solutions AMR101: Next Generation of Lipid Lowering Agents Initial Focus on Triglyceride (TG) Management Positioned to Be Best in Class 1st in Class Product Product for for High TGs on Very High TGs Statin Therapy Phase 3 Study Results: Demonstrated Efficacy and Saf
Slide 4: Investment Highlights
Investment Highlights Large Worldwide Multiple Underserved Patient Populations with High TG Levels Sales Potential Phase 3 Trials: Pure EPA Solution Showed Efficacy in Lowering TGs Differentiated Product with No Statistically Significant Increase in LDL-C (bad cholesterol) Phase 3 Trials Completed –
Slide 5: New Paradigm in Managing Cardiovascular Health
New Paradigm in Managing Cardiovascular Health Traditional Emerging Treatment Next Generation Physician Focus Therapy Triglycerides with No Statistically Significant LDL-C Increase in FOCUS LDL-C & Total Cholesterol Triglycerides (TGs-fats in MARINE; Statistically Significant blood stream) Decrease
Slide 6: Large Underpenetrated Market Opportunities
Large Underpenetrated Market Opportunities >100M People in Top 7 Markets for Initially Targeted Indications U.S. Adult Population Based on TG levels 150 Million Only 3.6% Treated with Rx Meds Future Potential AMR101 Initial Targets Included in REDUCE-IT Outcome Study 34 Million 36 Million Lovaza Ind
Slide 7: Differentiated Product (not head-to-head study data)
Differentiated Product (not head-to-head study data) LOVAZA (marketed) AMR101 (investigational) A Highly Purified Mixture of Fatty Acids Icosapent Ethyl (Single Active Ingredient) Ethyl EPA (465 mg) Ethyl-EPA (>960 mg) Ethyl DHA (375 mg) Additional omega 6, 7 & 9 (100mg) Other Omega-3 Acid Ethyl fat
Slide 8: Potential Competitive Advantages (not head-to-head data)
Potential Competitive Advantages (not head-to-head data) AMR101 (investigational) vs. Omega 3s vs. Fenofibrates (Lovaza / Omacor) ◼ TG Lowering without Increased LDL-C ◼ TG Lowering without Increased LDL-C ◼ Broader Potential Indication (>200- ◼ Incremental Effectiveness as Statin <500mg/dL) Potency
Slide 9: AMR101: Successful Phase 3 Clinical Trials
AMR101: Successful Phase 3 Clinical Trials MARINE (July 26, 2012 PDUFA) ANCHOR Patients with Very High Triglycerides Patients with Mixed Dyslipidemia (TG≥200mg/dL (≥500mg/dL) and <500mg/dL) on Statin Therapy • Achieved Primary Endpoint With Highly • Achieved All Endpoints with Statistically Statisti
Slide 10: Safety Comparable to Placebo in Both Trials
Safety Comparable to Placebo in Both Trials Well Tolerated No Treatment Related SAEs Lack of LDL-C Elevation May Eliminate Need to Increase Statin Dose Due to TG Therapy At Either Dose, No Significant Changes in Fasting Plasma Glucose Levels vs. Placebo MARINE Study Treatment-Emergent Advers
Slide 11: Multiple Clinical Needs: First Targeted Indication
Multiple Clinical Needs: First Targeted Indication Very High TGs POPULATION >500 mg/dL ◼ Pancreatitis RISKS TO ◼ Cardiovascular Disease PATIENTS MARINE $4-6B PDUFA Market U.S. MARKET ◼ 3.8 M Patients July 26, 2012 Opportunity ◼ Cardiologist, Endocrinologist, PRESCRIBERS Lipidologist ◼ Some Primary C
Slide 12: Multiple Clinical Needs: Second Targeted Indication
Multiple Clinical Needs: Second Targeted Indication Very High TGs High TGs on Statin Therapy >200 mg/dL to POPULATION >500 mg/dL <500 mg/dL ◼ Pancreatitis ◼ Cardiovascular Disease RISKS TO ◼ Cardiovascular Disease ◼ Multiple Lipid Disorders PATIENTS ANCHOR ◼ 36 M Patients with TGs Study Data $40B U.
Slide 13: Multiple Clinical Needs: Future Potential Indications
Multiple Clinical Needs: Future Potential Indications Very High TGs High TGs on Moderate TGs Statin Therapy >200 mg/dL to >150 mg/dL POPULATION >500 mg/dL <500 mg/dL to 199 mg/dL ◼ Pancreatitis ◼ Cardiovascular Disease ◼ Significant Additional RISKS TO ◼ Cardiovascular Disease ◼ Multiple Lipid Disor
Slide 14: Multiple Clinical Needs: Future Potential Indications
Multiple Clinical Needs: Future Potential Indications Very High TGs High TGs on Moderate TGs Statin Therapy >200 mg/dL to >150 mg/dL POPULATION >500 mg/dL <500 mg/dL to 199 mg/dL ◼ Pancreatitis ◼ Cardiovascular Disease ◼ Significant Additional RISKS TO ◼ Cardiovascular Disease ◼ Multiple Lipid Disor
Slide 15: AMR101 Cardiovascular Outcomes Study: REDUCE-IT
AMR101 Cardiovascular Outcomes Study: REDUCE-IT PURPOSE COST Evaluate AMR101 Effectiveness in ~$100-125M via CRO Reducing Cardiovascular Events Less than $25M Through 2012 DESIGN OPPORTUNITY SPA Agreement Reached in Aug 2011 MARINE Approval and Getting – ~8,000 Patients on Optimized Statin
Slide 16: JELIS Study: Ethyl-EPA Reduces Coronary Events
JELIS Study: Ethyl-EPA Reduces Coronary Events 18,645 Japanese Men and Women Randomized to Statin Alone or Statin + Ethyl-EPA (Epadel) and Followed for 5 Years TOTAL COHORT SUB GROUP (No Pre-specified Minimum TG level) (TG>150 mg/dL and HDL < 40 mg/dL) Cumulative Incidence of Major Coronary Events (
Slide 17: Commercialization Strategy
Commercialization Strategy Market Launch Parallel Processing All Options Supply Global Supply Chain for Diversity and Cost Competition Well Positioned for Multiple Patents with Exclusivity Through 2030 IP 16 Pending U.S. Patent Applications across 11 U.S. Patent Families MARINE NDA Accepte
Slide 18: Experienced Management Team
Experienced Management Team Years Experience Joseph Zakrzewski Former COO of Reliant Pharmaceuticals Executive Chairman and (Which Launched Lovaza and Was Sold to GSK for $1.6B) >20 Chief Executive Officer and Former VP Corporate Business Development Eli Lilly John Thero Former Senior Roles for Mult
Slide 19: Milestone Summary
Milestone Summary History of Positive Achievement Looking Ahead in 2012 All 2010 – 2011 Milestones Achieved Ahead of or on Schedule ANCHOR Data Publication MARINE and ANCHOR Trial Results Prosecution of 16 U.S. Patent Applications REDUCE-IT Commenced NCE Status Determination Global Supply Chain Expa
Slide 20: Capitalization Summary
Capitalization Summary September 30, 2011 ($ Millions, Except per Share Amounts) CASH $125.9 Prior to $150M financing done Jan’12(1) DEBT None Common Stock and Equivalent Shares COMMON SHARES 135.8 OPTIONS 10.8 Average Exercise Price of $5.11 WARRANTS 21.1 Average Exercise Price of $1.48 TOTAL IF AL
Slide 21: Investment Highlights
Investment Highlights Large Worldwide Multiple Underserved Patient Populations with High TG Levels Sales Potential Phase 3 Trials: Pure EPA Solution Showed Efficacy in Lowering TGs Differentiated Product with No Statistically Significant Increase in LDL-C (bad cholesterol) Phase 3 Trials Completed –
Slide 22: Managing Lipids for Improved Cardiovascular Health
Managing Lipids for Improved Cardiovascular Health INVESTOR PRESENTATION February 2012 Nasdaq: AMRN